Full-Time

Senior Global Sourcing Manager

Posted on 8/16/2025

Praxis Precision Medicines

Praxis Precision Medicines

201-500 employees

Clinical-stage biopharma developing CNS therapies

No salary listed

Remote in India

Remote

Remote role based in India with occasional travel as needed.

Category
People & HR (4)
, , ,
Requirements
  • Bachelor's degree in chemical engineering, Pharmacy, or Chemistry
  • 10+ years of sourcing experience within pharmaceutical or CDMO settings
  • Deep knowledge of global API supply chains and regulatory-compliant sourcing
  • Proven success in negotiating with international suppliers and managing complex vendor networks
  • Strong analytical, communication, and cross-functional collaboration skills
  • Comfortable with domestic and international travel
  • The physical and mental requirements of our roles include but are not limited to regular use of a computer, devices or other office equipment, clear communication, and occasional movement. You'll need comfort with screen work, basic hand coordination, and focus.
Responsibilities
  • Source and qualify global suppliers of GMP and non-GMP raw materials, high-purity solvents, and specialty reagents.
  • Lead supplier identification, qualification, and onboarding in collaboration with Quality and Regulatory teams.
  • Negotiate pricing and contracts while managing vendor performance and driving continuity of supply.
  • Ensure compliance with GMP, ICH Q7, USFDA, and ECHA/REACH requirements across the supply base.
  • Drive cost and working capital improvements through strategic sourcing tactics such as dual sourcing, volume bundling, and incoterms optimization.
  • Collaborate cross-functionally with R&D, Process Development, and Manufacturing teams to support tech transfer and scale-up.
  • Conduct risk assessments and build mitigation plans for critical material categories.
  • Monitor global market trends and geopolitical factors impacting raw material availability and pricing.
Desired Qualifications
  • MBA in SCM/Operations a plus
  • Prior experience in a sourcing or procurement role within established CDMOs is highly desirable
  • Familiarity with sourcing controlled substances, fluorinated reagents, or hazardous materials
Praxis Precision Medicines

Praxis Precision Medicines

View

Praxis Precision Medicines develops therapies for central nervous system (CNS) disorders, with a focus on conditions caused by neuronal imbalance and genetic epilepsies. Its products aim to restore balance in CNS networks by applying genetic epilepsy insights, progressing through clinical development toward potential commercialization. What sets Praxis apart is its commitment to patient-guided development, incorporating patient and caregiver needs into therapy design, alongside strategic partnerships with other healthcare entities. The company's goal is to deliver effective CNS treatments to patients and caregivers and advance collaborations that support clinical development and eventual market access.

Company Size

201-500

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA accepted relutrigine NDA with PDUFA September 27, 2026, ulixacaltamide January 29, 2027.
  • $1.4B cash reserves from $575M January 2026 offering fund operations through 2028.
  • Driehaus $80.5M, Affinity $55M investments signal institutional confidence in dual launches.

What critics are saying

  • Jazz suvecaltamide approved March 15, 2026, competes directly with ulixacaltamide in $2B market.
  • FDA clinical hold on vormatrigine May 10, 2026, destroys 60% pipeline value.
  • $120M quarterly burn depletes cash by mid-2028, forces dilutive financing.

What makes Praxis Precision Medicines unique

  • Praxis translates genetic epilepsy insights into therapies for CNS neuronal imbalance.
  • Relutrigine achieves 46% motor seizure reduction in Phase 2, 30% seizure-free patients.
  • Ulixacaltamide shows positive Phase 3 data for essential tremor, NDA filed early 2026.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Praxis Precision Medicines who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Stock Options

Company Equity

Performance Bonus

Unlimited Paid Time Off

Paid Holidays

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-3%

2 year growth

-1%
Yahoo Finance
Mar 13th, 2026
Biotech Praxis secures $80.5M investment from Driehaus as stock soars 685% ahead of dual FDA filings

Driehaus Capital Management has invested $80.5 million in Praxis Precision Medicines, purchasing 432,510 shares and bringing its stake to 1.87% of assets under management. The transaction, disclosed on 17 February 2026, increased Driehaus's position value by $248.5 million, reflecting both the purchase and share price appreciation. Praxis shares have surged 685% over the past year to $303.37, giving the company an $8.4 billion market capitalisation. The biotech firm recently submitted two FDA applications: ulixacaltamide for essential tremor and relutrigine for rare developmental epilepsies. CEO Marcio Souza estimates the company's four late-stage programmes could generate over $20 billion in revenue if commercialised. Praxis ended 2025 with $926 million in cash and raised an additional $621 million in January, providing funding through 2028.

Intellectia.AI
Feb 16th, 2026
Affinity Asset Advisors Acquires New Stake in Praxis Precision Medicines

- **New Investment Disclosure**: On February 13, 2026, Affinity Asset Advisors disclosed a new position by acquiring 185,000 shares of Praxis Precisio...

Yahoo Finance
Feb 14th, 2026
Affinity Asset Advisors bets $55M on Praxis Precision Medicines as biotech surges 266% ahead of drug applications

Affinity Asset Advisors has disclosed a new position in Praxis Precision Medicines, acquiring 185,000 shares valued at $54.53 million during the fourth quarter. The stake represents 3.11% of the fund's reportable assets. Praxis shares were trading at $317.25 as of 13 February 2026, up 266% over the past year. The Boston-based clinical-stage biotechnology company develops therapies for central nervous system disorders, with lead candidates targeting major depressive disorder, essential tremor and epilepsy. The company expects two new drug application submissions by mid-February and holds approximately $956 million in cash and investments, sufficient to fund operations into 2028. Third-quarter research and development expense reached $65.8 million, whilst net loss widened to $73.9 million.

Praxis Precision Medicines
Feb 6th, 2026
Praxis Precision Medicines Announces $110 Million Financing - Praxis Precision Medicines, Inc.

Participation from top-tier healthcare investors recognizes momentum across breadth of its CNS therapeutics portfolio CAMBRIDGE, Mass.--Praxis Precision Medicines, Inc., a clinical-stage company translating genetic insights into the development of therapies for people with central nervous system

Praxis Precision Medicines
Feb 6th, 2026
Praxis Precision Medicines Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - Praxis Precision Medicines, Inc.

CAMBRIDGE, Mass. , Oct. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced

INACTIVE